AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABCL AbCellera Biologics

Pre-Mkt 07-17 06:04:10 EDT

6.16

-0.58

-8.61%

盘前6.04

-0.12-1.95%

06:03 EDT

High6.66	Low6.05	Vol7.55M
Open6.65	D1 Closing6.74	Amplitude9.05%
Mkt Cap1.88B	Tradable Cap1.26B	Total Shares305.26M
T/O47.12M	T/O Rate3.68%	Tradable Shares205.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABCL","market":"US","secType":"STK","nameCN":"AbCellera Biologics","latestPrice":6.16,"timestamp":1784232000000,"preClose":6.74,"halted":0,"volume":7547837,"hourTrading":{"tag":"盘前","latestPrice":6.04,"preClose":6.16,"latestTime":"06:03 EDT","volume":45097,"amount":270248.95865499997,"timestamp":1784282605723,"change":-0.12,"changeRate":-0.019481,"amplitude":0.032451},"delay":0,"changeRate":-0.08605341246290801,"floatShares":204999999,"shares":305264947,"eps":-0.480392,"marketStatus":"Pre-Mkt","change":-0.58,"latestTime":"07-17 06:04:10 EDT","open":6.65,"high":6.66,"low":6.05,"amount":47124756.52143709,"amplitude":0.090504,"askPrice":6.1,"askSize":2,"bidPrice":6,"bidSize":117,"shortable":0,"etf":0,"ttmEps":-0.480392,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1784295000000},"marketStatusCode":1,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":6.16,"preHourTrading":{"tag":"盘前","latestPrice":6.04,"preClose":6.16,"latestTime":"06:03 EDT","volume":45097,"amount":270248.95865499997,"timestamp":1784282605723,"change":-0.12,"changeRate":-0.019481,"amplitude":0.032451},"postHourTrading":{"tag":"盘后","latestPrice":6.1999,"preClose":6.16,"latestTime":"19:58 EDT","volume":157619,"amount":970246.1565,"timestamp":1784246324318,"change":0.0399,"changeRate":0.006477,"amplitude":0.037338},"volumeRatio":1.4933370364953624,"impliedVol":1.0944,"impliedVolPercentile":0.672},"requestUrl":"/m/hq/s/ABCL/wiki","defaultTab":"wiki","newsList":[{"id":"2651495048","title":"Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651495048","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651495048?lang=en_us&edition=fundamental","pubTime":"2026-07-16 04:20","pubTimestamp":1784146809,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alumis Inc. (ALMS) and AbCellera Biologics (ABCL) wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alumis-inc-alms-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alumis-inc-alms-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","XLV","LU0029874061.USD","BK4588","LABU","XBI","ALMS","BK4535","BK4585","HCSG","ABCL","BK4581","BK4121","BK4007","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650975626","title":"AbCellera Biologics call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2650975626","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650975626?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:05","pubTimestamp":1783613111,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in AbCellera (ABCL) Biologics with 3,839 calls trading, 1.1x expected, and implied vol increasing over 2 points to 114...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-call-volume-above-normal-and-directionally-bullish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-call-volume-above-normal-and-directionally-bullish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","ABCL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649595800","title":"Press Release: Abcellera to Report Second Quarter 2026 Financial Results on August 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2649595800","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649595800?lang=en_us&edition=fundamental","pubTime":"2026-07-08 06:13","pubTimestamp":1783462380,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia--(BUSINESS WIRE)--July 07, 2026--AbCellera (Nasdaq: ABCL) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026, and hold an earnings confere","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4535","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649372089","title":"Abcellera Schedules Q2 2026 Results, Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2649372089","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649372089?lang=en_us&edition=fundamental","pubTime":"2026-07-08 04:05","pubTimestamp":1783454714,"startTime":"0","endTime":"0","summary":"AbCellera schedules Q2 2026 results, earnings callAbCellera will report second-quarter 2026 financial results on Aug. 5, 2026.An earnings conference call is scheduled for Aug. 5, 2026 at 2:00 p.m. PT ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL5Yzns:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4535","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649215982","title":"Abcellera Biologics Raised to Buy from Hold by Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2649215982","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649215982?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:59","pubTimestamp":1783425540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABCL/analyst-ratings(END) Dow Jones NewswiresJuly 07, 2026 07:59 ET","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4535","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984068","title":"Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target is $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984068","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984068?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:33","pubTimestamp":1783424025,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (ABCL) has an average rating of buy and mean price target of $10.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649981101","title":"Abcellera Biologics Inc : Benchmark Raises to Buy from Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2649981101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649981101?lang=en_us&edition=fundamental","pubTime":"2026-07-07 18:53","pubTimestamp":1783421580,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4121","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649988008","title":"What AbCellera Biologics (ABCL)'s New Oncology Veteran Director Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2649988008","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649988008?lang=en_us&edition=fundamental","pubTime":"2026-07-07 15:31","pubTimestamp":1783409487,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc. recently appointed Lynn Seely, M.D., president and CEO of Lyell Immunopharma and former Myovant Sciences chief executive, to its Board of Directors as an independent director, adding deep experience in oncology and commercializing complex therapies.\nHer background leading drug programs from first-in-human trials through approvals and major acquisitions may influence how AbCellera shapes its pipeline priorities and commercialization plans.\nWe’ll now examine how adding...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/what-abcellera-biologics-abcls-new-oncology-veteran-director","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/what-abcellera-biologics-abcls-new-oncology-veteran-director","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4535","BK4121","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649674275","title":"Abcellera Files Form 3 as Director Lynn Seely Reports no Beneficial Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2649674275","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649674275?lang=en_us&edition=fundamental","pubTime":"2026-07-07 06:15","pubTimestamp":1783376147,"startTime":"0","endTime":"0","summary":"AbCellera files Form 3 as director Lynn Seely reports no beneficial ownershipAbCellera Biologics filed an initial Form 3 showing Lynn Seely as a director as of June 30, 2026.Disclaimer:This news brief","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL6vHdGl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4535","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649767096","title":"AbCellera Biologics Adds Independent Director to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2649767096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649767096?lang=en_us&edition=fundamental","pubTime":"2026-07-07 03:17","pubTimestamp":1783365451,"startTime":"0","endTime":"0","summary":"The latest update is out from AbCellera Biologics ( ($ABCL) ). On June 30, 2026, AbCellera Biologics Inc. appointed Lynn Seely, M.D., as an indepen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-adds-independent-director-to-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-adds-independent-director-to-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","ABCL","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649624735","title":"AbCellera apponts Lynn Seely to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2649624735","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649624735?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:15","pubTimestamp":1783343729,"startTime":"0","endTime":"0","summary":"AbCellera (ABCL) announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. Dr. Seely currently serves as...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-apponts-lynn-seely-to-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-apponts-lynn-seely-to-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","ABCL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649624680","title":"Abcellera Appoints Lyell CEO Lynn Seely to Board as Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2649624680","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649624680?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:01","pubTimestamp":1783342880,"startTime":"0","endTime":"0","summary":"AbCellera appoints Lyell CEO Lynn Seely to board as independent directorAbCellera appointed Lynn Seely, M.D., to its board as an independent director.Seely is president and CEO of Lyell Immunopharma, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL7DYd50:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","ABCL","BK4121","BK4539","BK4535","LYEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649624519","title":"Abcellera Appoints DR. Lynn Seely to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2649624519","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649624519?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:00","pubTimestamp":1783342802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUA9WXYY3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","ABCL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646831975","title":"Is AbCellera (ABCL) Using the Jazz Partnership to Quietly Redefine Its Oncology Platform Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2646831975","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646831975?lang=en_us&edition=fundamental","pubTime":"2026-06-28 07:12","pubTimestamp":1782601930,"startTime":"0","endTime":"0","summary":"Earlier this month, Jazz Pharmaceuticals and AbCellera Biologics announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T‑cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors, anchored by US$56 million in upfront payments and the potential for very large milestone packages per program plus royalties.\nThe deal underscores external validation of AbCellera’s T‑cell engager platform, which spans...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/is-abcellera-abcl-using-the-jazz-partnership-to-quietly-rede","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/is-abcellera-abcl-using-the-jazz-partnership-to-quietly-rede","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABCL","BK4121","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646438898","title":"AbCellera Biologics call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2646438898","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646438898?lang=en_us&edition=fundamental","pubTime":"2026-06-25 03:11","pubTimestamp":1782328264,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in AbCellera (ABCL) Biologics with 12,052 calls trading, 3x expected, and implied vol increasing almost 7 points to 10...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-call-volume-above-normal-and-directionally-bullish-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-call-volume-above-normal-and-directionally-bullish-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABCL","BK4535","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644060514","title":"Why AbCellera Biologics (ABCL) Is Up 5.5% After New Jazz T-Cell Engager Collaboration Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2644060514","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644060514?lang=en_us&edition=fundamental","pubTime":"2026-06-20 18:20","pubTimestamp":1781950850,"startTime":"0","endTime":"0","summary":"On 17 June 2026, Jazz Pharmaceuticals and AbCellera Biologics announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors, including US$56,000,000 in upfront payments and eligibility for very large potential milestones and tiered royalties.\nAn interesting aspect of this agreement is that Jazz receives exclusive, worldwide development and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/why-abcellera-biologics-abcl-is-up-55-after-new-jazz-t-cell","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/why-abcellera-biologics-abcl-is-up-55-after-new-jazz-t-cell","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4535","BK4121","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644085611","title":"Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644085611","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644085611?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:40","pubTimestamp":1781786435,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-amylyx-pharmaceuticals-inc-amlx-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-amylyx-pharmaceuticals-inc-amlx-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4121","XLV","ZYME","BK4588","BK4137","BK4535","ABCL","AMLX","LU0128526141.USD","BK4585","HCSG","LU0029874061.USD","BK4581","BK4007","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644437847","title":"Jazz Pharma, AbCellera ink antibody deal worth up to $876 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644437847","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644437847?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:42","pubTimestamp":1781696527,"startTime":"0","endTime":"0","summary":"Jazz Pharma, AbCellera ink antibody deal worth up to $876 millionJune 17 (Reuters) - Jazz Pharmaceuticals JAZZ.O has signed a research collaboration and licensing agreement with Canada's AbCellera ABC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL4N42P0T0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4535","IE00BN0W2W23.USD","JAZZ","LU0823416689.USD","BK4007","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4533","LU0154245756.USD","BK4532","BK4121","LU0889565916.HKD","LU0320765992.SGD","LU0154245673.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644743145","title":"Jazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact","url":"https://stock-news.laohu8.com/highlight/detail?id=2644743145","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644743145?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:33","pubTimestamp":1781695980,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals and AbCellera agreed to a deal worth up to $876 million to discover and develop treatments for gastrointestinal cancers and other solid tumors.The agreement includes plans for preclinical research collaboration, options and licensing of T-cell engaging multispecific antibodies.AbCellera, which has a T-cell engager platform, will perform discovery and early-stage research for two initial programs, with a commitment to start a third program within 12 months.Jazz is granted an option in connection with each research program and, once it exercises its option, will have exclusive, global rights to develop and commercialize each program.AbCellera will receive $56 million in total upfront payments for the first two research programs, plus an additional $28 million due when the third program starts.If Jazz exercises its option for development, AbCellera will also be eligible to receive up to $792 million per program in option fees and development, regulatory and commercial","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","LU0154245756.USD","ABCL","LU0889565916.HKD","IE00BN0W2W23.USD","BK4121","LU0823416689.USD","BK4007","JAZZ","BK4533","LU0320765992.SGD","IE00BN0W2V16.EUR","BK4535","LU0109394709.USD","LU0154245673.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644435317","title":"Jazz Pharmaceuticals, AbCellera collaborate for TCE multispecific antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2644435317","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644435317?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:14","pubTimestamp":1781694854,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals (JAZZ) and AbCellera (ABCL) announced a preclinical research collaboration, option and license agreement to discover and devel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jazz-pharmaceuticals-abcellera-collaborate-for-tce-multispecific-antibodies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jazz-pharmaceuticals-abcellera-collaborate-for-tce-multispecific-antibodies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","LU0154245673.USD","BK4532","BK4007","LU0320765992.SGD","LU0823416689.USD","IE00BN0W2W23.USD","BK4121","IE00BN0W2T93.GBP","BK4533","LU0889565916.HKD","LU0109394709.USD","IE00BN0W2V16.EUR","LU0154245756.USD","JAZZ","ABCL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abcellera.com","stockEarnings":[{"period":"1week","weight":-0.155},{"period":"1month","weight":0.2102},{"period":"3month","weight":0.5362},{"period":"6month","weight":0.4951},{"period":"1year","weight":0.5172},{"period":"ytd","weight":0.8012}],"compareEarnings":[{"period":"1week","weight":-0.0013},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.0854},{"period":"1year","weight":0.2027},{"period":"ytd","weight":0.1009}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.002724},{"month":2,"riseRate":0,"avgChangeRate":-0.119779},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.059327},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.055905},{"month":5,"riseRate":0.666667,"avgChangeRate":0.054331},{"month":6,"riseRate":0.5,"avgChangeRate":0.144975},{"month":7,"riseRate":0.5,"avgChangeRate":0.003022},{"month":8,"riseRate":0.4,"avgChangeRate":-0.080936},{"month":9,"riseRate":0.6,"avgChangeRate":0.036664},{"month":10,"riseRate":0.6,"avgChangeRate":0.00539},{"month":11,"riseRate":0.6,"avgChangeRate":-0.007841},{"month":12,"riseRate":0.2,"avgChangeRate":-0.030878}],"exchange":"NASDAQ","name":"AbCellera Biologics","nameEN":"AbCellera Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AbCellera Biologics,ABCL,AbCellera Biologics股票,AbCellera Biologics股票老虎,AbCellera Biologics股票老虎国际,AbCellera Biologics行情,AbCellera Biologics股票行情,AbCellera Biologics股价,AbCellera Biologics股市,AbCellera Biologics股票价格,AbCellera Biologics股票交易,AbCellera Biologics股票购买,AbCellera Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}